Report error Found 415 Enz. Inhib. hit(s) with Target = 'Epidermal growth factor receptor [1-770,'NPG',771-1210]'
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 0.262nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 0.290nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 0.308nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 0.330nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataKd: <0.5nMAssay Description:In some assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and inf...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 0.537nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 0.706nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 0.724nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 0.801nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 0.837nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 0.875nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 0.979nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 0.988nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 1.05nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 1.10nMAssay Description:Cell viability was determined using the Cell Titer Glo assay (Promega) as previously described. Briefly, 2000-3000 cells per well were plated in 384-...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 1.29nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 1.29nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 1.33nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 1.36nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 1.55nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 1.60nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 1.82nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 1.83nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 1.86nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 1.92nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 1.97nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 2nMAssay Description:Cell viability was determined using the Cell Titer Glo assay (Promega) as previously described. Briefly, 2000-3000 cells per well were plated in 384-...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 2.02nMAssay Description:PNPG Assay: Two -glucuronidase activity assays were employed to examine the potency of inhibitors both in vitro and in cell-based studies. An absorba...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 2.06nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 2.08nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 2.21nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 2.21nMAssay Description:PNPG Assay: Two -glucuronidase activity assays were employed to examine the potency of inhibitors both in vitro and in cell-based studies. An absorba...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 2.30nMAssay Description:Cell viability was determined using the Cell Titer Glo assay (Promega) as previously described. Briefly, 2000-3000 cells per well were plated in 384-...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 2.31nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 2.41nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 2.46nMAssay Description:The compound of the present invention had a good inhibitory activity on an EGFR kinase, and the IC50 values were all less than 10 μM. The specific ex...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 2.72nMAssay Description:The compound of the present invention had a good inhibitory activity on an EGFR kinase, and the IC50 values were all less than 10 μM. The specific ex...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 2.82nMAssay Description:PNPG Assay: Two -glucuronidase activity assays were employed to examine the potency of inhibitors both in vitro and in cell-based studies. An absorba...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 2.82nMAssay Description:The compound of the present invention had a good inhibitory activity on an EGFR kinase, and the IC50 values were all less than 10 μM. The specific ex...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 2.84nMAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
Ligand Info
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 2.92nMAssay Description:Compounds were tested on human Nav1.7 (hNav1.7) expressed stably in 293 cells, which have no endogenous sodium channels. Two forms of whole-cell patc...More data for this Ligand-Target Pair
Ligand Info
















































